X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
male (18) 18
female (15) 15
index medicus (13) 13
aged (12) 12
health care sciences & services (11) 11
oncology (10) 10
adult (8) 8
aged, 80 and over (7) 7
chemotherapy (7) 7
medicine & public health (7) 7
middle aged (7) 7
analysis (6) 6
health policy & services (6) 6
pharmacology & pharmacy (6) 6
survival (6) 6
cancer (5) 5
care and treatment (5) 5
clinical trials (5) 5
economics (5) 5
follow-up studies (5) 5
health technology assessment (5) 5
hospitalization (5) 5
internal medicine (5) 5
prostate cancer (5) 5
risk factors (5) 5
studies (5) 5
therapy (5) 5
cancer therapies (4) 4
comparative analysis (4) 4
cost-benefit analysis (4) 4
cross-sectional studies (4) 4
databases, factual (4) 4
disease (4) 4
drug therapy (4) 4
health economics (4) 4
health policy (4) 4
impact (4) 4
medical care, cost of (4) 4
medicine, research & experimental (4) 4
metaanalysis (4) 4
outcomes (4) 4
patients (4) 4
quality of life (4) 4
research (4) 4
research article (4) 4
treatment outcome (4) 4
united states (4) 4
usage (4) 4
young adult (4) 4
adolescent (3) 3
cardiac & cardiovascular systems (3) 3
cardiology (3) 3
cohort studies (3) 3
cost of illness (3) 3
cost-effectiveness (3) 3
data processing (3) 3
diagnosis (3) 3
endocrinology (3) 3
epidemiology (3) 3
health administration (3) 3
health aspects (3) 3
health-related quality of life (3) 3
hematology (3) 3
medical research (3) 3
medical treatment (3) 3
medicine, general & internal (3) 3
metastasis (3) 3
mortality (3) 3
patient outcomes (3) 3
pharmacoeconomics and health outcomes (3) 3
prednisone (3) 3
prognosis (3) 3
public health (3) 3
public health, environmental and occupational health (3) 3
quality of life research (3) 3
quality-of-life (3) 3
retrospective studies (3) 3
rheumatology (3) 3
risk (3) 3
saskatchewan (3) 3
severity of illness index (3) 3
statistical analysis (3) 3
stroke - epidemiology (3) 3
survival analysis (3) 3
time factors (3) 3
validity (3) 3
abiraterone acetate (2) 2
accuracy (2) 2
acetic acid (2) 2
alternative medicine (2) 2
alzheimer's disease (2) 2
androgens (2) 2
antipsychotic agents - administration & dosage (2) 2
beta-thalassemia major (2) 2
bias (2) 2
canada (2) 2
cancer patients (2) 2
cardiology and cardiovascular medicine (2) 2
child (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC health services research, ISSN 1472-6963, 2011, Volume 11, Issue 1, pp. 349 - 349
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e21623 - e21623
Journal Article
PharmacoEconomics, ISSN 1170-7690, 6/2014, Volume 32, Issue 6, pp. 533 - 546
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 04/2018, Volume 21, Issue 4, p. 416
Objectives Treatment landscape in prostate cancer has changed dramatically with the emergence of new medicines in the past few years. The traditional survival... 
Validation | Drugs | Death & dying | Partition | Statistical analysis | Clinical trials | Data processing | Clinical research | Cancer therapies | Survival | Flexibility | Interim | Clinical outcomes | Standard Progressive Matrices | Confidence intervals | Chemotherapy | Androgens | Accuracy | Simulation | Mathematical models | Acetic acid | Prostate cancer | Prostate
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 5946 - 5946
Abstract INTRODUCTION: Several new agents and regimens are available for the treatment of relapsed refractory multiple myeloma (RRMM). Comparison of all these... 
Journal Article
Circulation, ISSN 0009-7322, 01/2010, Volume 121, Issue 1, pp. 71 - 79
Background-In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by... 
Infarction | Coronary disease | Thrombus | Cost- benefit analysis | Revascularization | revascularization | CARDIAC & CARDIOVASCULAR SYSTEMS | CONFIDENCE-INTERVALS | CARDIOVASCULAR EVENTS | infarction | thrombus | coronary disease | IMPACT | cost-benefit analysis | PERIPHERAL VASCULAR DISEASE | ST-SEGMENT ELEVATION | HEMATOLOGY | CLINICAL-OUTCOMES | Platelet Aggregation Inhibitors - economics | Prasugrel Hydrochloride | Thiophenes - therapeutic use | United States - epidemiology | Myocardial Infarction - mortality | Follow-Up Studies | Ticlopidine - therapeutic use | Acute Coronary Syndrome - economics | Humans | Acute Coronary Syndrome - mortality | Hemorrhage - mortality | Piperazines - economics | Angioplasty, Balloon, Coronary | Drug Costs - statistics & numerical data | Life Expectancy | Ticlopidine - economics | Myocardial Infarction - economics | Thiophenes - economics | Stroke - mortality | Platelet Aggregation Inhibitors - therapeutic use | Databases, Factual | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Thrombolytic Therapy - economics | Combined Modality Therapy | Piperazines - therapeutic use | Ticlopidine - analogs & derivatives | Acute Coronary Syndrome - drug therapy | Outcome and Process Assessment (Health Care) - economics | Myocardial Infarction - drug therapy | Cost-Benefit Analysis | Hospitalization - economics | Usage | Patient outcomes | Clopidogrel | Drug therapy | Comparative analysis | Health aspects | Heart attack
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 04/2019, Volume 35, Issue 4, pp. 569 - 576
Objective: Brigatinib, ceritinib, and alectinib are approved to treat crizotinib-refractory anaplastic lymphoma kinase-positive (ALK+) non-small cell lung... 
Brigatinib | ALK + NSCLC | Alectinib | Ceritinib | Indirect comparison | ALK + NSCLC | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ALK plus NSCLC | SAFETY | OPEN-LABEL | CHEMOTHERAPY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.